A carregar...
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas
Our group previously demonstrated that sarcoma cell lines were insensitive to epidermal growth factor receptor (EGFR) inhibitor gefitinib monotherapy. PENAO, an anti-tumour metabolic compound created in our laboratory, is currently in clinical trials. Considering the positive regulation of tumour en...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6967775/ https://ncbi.nlm.nih.gov/pubmed/32002123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27416 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|